Travere Therapeutics, Inc. NASDAQ:TVTX

Travere Therapeutics stock price today

$17.2
-0.08
-0.46%
Financial Health
0
1
2
3
4
5
6
7
8
9

Travere Therapeutics stock price monthly change

+76.33%
month

Travere Therapeutics stock price quarterly change

+76.33%
quarter

Travere Therapeutics stock price yearly change

+81.89%
year

Travere Therapeutics key metrics

Market Cap
1.45B
Enterprise value
1.68B
P/E
-5.17
EV/Sales
10.78
EV/EBITDA
-7.19
Price/Sales
8.56
Price/Book
31.21
PEG ratio
0.33
EPS
-5.06
Revenue
183.22M
EBITDA
-349.96M
Income
-161.12M
Revenue Q/Q
-27.40%
Revenue Y/Y
-16.91%
Profit margin
-178.34%
Oper. margin
-311.35%
Gross margin
-4.86%
EBIT margin
-311.35%
EBITDA margin
-191%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Travere Therapeutics stock price history

Travere Therapeutics stock forecast

Travere Therapeutics financial statements

Average Price Target
Last Year

$22.45

Potential upside: 30.54%

Based on estimate of 9 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Travere Therapeutics, Inc. (NASDAQ:TVTX): Profit margin
Jun 2023 59.69M -85.63M -143.44%
Sep 2023 37.09M 150.73M 406.35%
Dec 2023 45.05M -90.17M -200.12%
Mar 2024 41.37M -136.06M -328.86%
Travere Therapeutics, Inc. (NASDAQ:TVTX): Debt to assets
Jun 2023 736429000 619.94M 84.18%
Sep 2023 832850000 553.08M 66.41%
Dec 2023 788913000 588.10M 74.55%
Mar 2024 663547000 589.47M 88.84%
Travere Therapeutics, Inc. (NASDAQ:TVTX): Cash Flow
Jun 2023 -69.29M -23.55M 2.26M
Sep 2023 -59.13M 133.31M -634K
Dec 2023 -70.47M -16.95M 124K
Mar 2024 -119.00M 104.89M -525K

Travere Therapeutics alternative data

Travere Therapeutics, Inc. (NASDAQ:TVTX): Employee count
Sep 2023 462
Oct 2023 462
Nov 2023 462
Dec 2023 462
Jan 2024 462
Feb 2024 462
Mar 2024 380
Apr 2024 380
May 2024 380
Jun 2024 380
Jul 2024 380

Travere Therapeutics other data

43.91% -56.09%
of TVTX is owned by hedge funds
27.99M -44.97M
shares is hold by hedge funds

Travere Therapeutics, Inc. (NASDAQ:TVTX): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 17828
Feb 2024 0 41657
Apr 2024 0 54
Sep 2024 0 77969
Oct 2024 0 40000
Nov 2024 0 12090
Dec 2024 0 15000
Transaction Date Insider Security Shares Price per share Total value Source
Option
CALVIN SANDRA officer: SVP, CHIEF ACCOUNTING ..
Common Stock 15,000 $12.67 $190,050
Sale
CALVIN SANDRA officer: SVP, CHIEF ACCOUNTING ..
Common Stock 15,000 $17.22 $258,285
Option
CALVIN SANDRA officer: SVP, CHIEF ACCOUNTING ..
Employee stock option (right to buy) 15,000 $12.67 $190,050
Option
CALVIN SANDRA officer: SVP, CHIEF ACCOUNTING ..
Common Stock 15,000 $12.67 $190,050
Sale
CALVIN SANDRA officer: SVP, CHIEF ACCOUNTING ..
Common Stock 12,090 $18.3 $221,259
Option
CALVIN SANDRA officer: SVP, CHIEF ACCOUNTING ..
Employee stock option (right to buy) 15,000 $12.67 $190,050
Option
LYONS GARY A director
Common Stock 40,000 $10.48 $419,200
Sale
LYONS GARY A director
Common Stock 21,179 $14.35 $303,876
Sale
LYONS GARY A director
Common Stock 18,821 $15.16 $285,232
Option
LYONS GARY A director
Stock option (right to buy) 40,000 $10.48 $419,200
Thursday, 19 December 2024
seekingalpha.com
Wednesday, 18 December 2024
globenewswire.com
Wednesday, 27 November 2024
accesswire.com
Tuesday, 26 November 2024
accesswire.com
Monday, 25 November 2024
globenewswire.com
Friday, 22 November 2024
accesswire.com
Monday, 18 November 2024
prnewswire.com
Saturday, 16 November 2024
accesswire.com
Thursday, 14 November 2024
accesswire.com
Wednesday, 13 November 2024
globenewswire.com
Tuesday, 12 November 2024
accesswire.com
Monday, 11 November 2024
marketbeat.com
Sunday, 10 November 2024
prnewswire.com
Friday, 8 November 2024
accesswire.com
Thursday, 7 November 2024
globenewswire.com
globenewswire.com
Wednesday, 6 November 2024
accesswire.com
Monday, 4 November 2024
globenewswire.com
accesswire.com
Saturday, 2 November 2024
prnewswire.com
Thursday, 31 October 2024
accesswire.com
seekingalpha.com
zacks.com
zacks.com
Sunday, 27 October 2024
accesswire.com
Saturday, 26 October 2024
globenewswire.com
Friday, 25 October 2024
prnewswire.com
Wednesday, 23 October 2024
accesswire.com
zacks.com
Monday, 21 October 2024
globenewswire.com
  • What's the price of Travere Therapeutics stock today?

    One share of Travere Therapeutics stock can currently be purchased for approximately $17.2.

  • When is Travere Therapeutics's next earnings date?

    Unfortunately, Travere Therapeutics's (TVTX) next earnings date is currently unknown.

  • Does Travere Therapeutics pay dividends?

    No, Travere Therapeutics does not pay dividends.

  • How much money does Travere Therapeutics make?

    Travere Therapeutics has a market capitalization of 1.45B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 31.5% to 145.24M US dollars.

  • What is Travere Therapeutics's stock symbol?

    Travere Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TVTX".

  • What is Travere Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Travere Therapeutics?

    Shares of Travere Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Travere Therapeutics's key executives?

    Travere Therapeutics's management team includes the following people:

    • Dr. Eric M. Dube Ph.D. Pres, Chief Executive Officer & Director(age: 52, pay: $1,130,000)
    • Dr. William E. Rote Ph.D. Senior Vice President of R&D(age: 62, pay: $716,580)
    • Dr. Noah L. Rosenberg M.D. Executive Advisor(age: 58, pay: $713,930)
    • Ms. Laura M. Clague CPA Chief Financial Officer(age: 66, pay: $707,620)
    • Ms. Elizabeth E. Reed Senior Vice President, Gen. Counsel & Corporation Sec.(age: 54, pay: $660,090)
  • How many employees does Travere Therapeutics have?

    As Jul 2024, Travere Therapeutics employs 380 workers.

  • When Travere Therapeutics went public?

    Travere Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 8 Nov 2012.

  • What is Travere Therapeutics's official website?

    The official website for Travere Therapeutics is travere.com.

  • Where are Travere Therapeutics's headquarters?

    Travere Therapeutics is headquartered at 3611 Valley Centre Drive, San Diego, CA.

  • How can i contact Travere Therapeutics?

    Travere Therapeutics's mailing address is 3611 Valley Centre Drive, San Diego, CA and company can be reached via phone at +888 9697879.

  • What is Travere Therapeutics stock forecast & price target?

    Based on 9 Wall Street analysts` predicted price targets for Travere Therapeutics in the last 12 months, the avarage price target is $22.45. The average price target represents a 30.54% change from the last price of $17.2.

Travere Therapeutics company profile:

Travere Therapeutics, Inc.

travere.com
Exchange:

NASDAQ

Full time employees:

380

Industry:

Biotechnology

Sector:

Healthcare

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

3611 Valley Centre Drive
San Diego, CA 92130

CIK: 0001438533
ISIN: US89422G1076
CUSIP: 89422G107